Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

U.S. faces crisis of burned-out healthcare workers

In a recent webinar hosted by U.S. News & World Report, top health care leaders detailed the serious threat that burnout presents to the resiliency of hospitals and health systems. Across the nation, front-line workers have been challenged by ever higher levels of stress caused by systemic changes to care delivery and exacerbated by COVID-19.

Before the pandemic, physicians were at twice the risk for burnout compared to the general population, and about 40% of those surveyed reported depression and suicidal ideation, said Dr. Victor Dzau, president of the National Academy of Medicine, during the webinar. Increases in patient volume, the demands of making health care more businesslike, the pressure of meeting more regulations and requirements and other factors have left providers feeling overwhelmed and with less time to spend one-on-one with patients, panelists noted.

Source: US News

https://www.usnews.com/news/health-news/articles/2021-11-15/us-faces-crisis-of-burned-out-health-care-workers

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!